111 related articles for article (PubMed ID: 36052503)
1. PRC2 Loss and DNMT Inhibition Boost Viral Mimicry in Cancer.
Guil S; Esteller M
Cancer Discov; 2022 Sep; 12(9):2020-2022. PubMed ID: 36052503
[TBL] [Abstract][Full Text] [Related]
2. PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.
Patel AJ; Warda S; Maag JLV; Misra R; Miranda-Román MA; Pachai MR; Lee CJ; Li D; Wang N; Bayshtok G; Fishinevich E; Meng Y; Wong EWP; Yan J; Giff E; Pappalardi MB; McCabe MT; Fletcher JA; Rudin CM; Chandarlapaty S; Scandura JM; Koche RP; Glass JL; Antonescu CR; Zheng D; Chen Y; Chi P
Cancer Discov; 2022 Sep; 12(9):2120-2139. PubMed ID: 35789380
[TBL] [Abstract][Full Text] [Related]
3. Poly Combs the Immune System: PRC2 Loss in Malignant Peripheral Nerve Sheath Tumors Can Dampen Immune Responses.
Natarajan SK; Venneti S
Cancer Res; 2019 Jul; 79(13):3172-3173. PubMed ID: 31262833
[TBL] [Abstract][Full Text] [Related]
4. PRC2 loss drives MPNST metastasis and matrix remodeling.
Brockman QR; Scherer A; McGivney GR; Gutierrez WR; Voigt AP; Isaacson AL; Laverty EA; Roughton G; Knepper-Adrian V; Darbro B; Tanas MR; Stipp CS; Dodd RD
JCI Insight; 2022 Oct; 7(20):. PubMed ID: 36066973
[TBL] [Abstract][Full Text] [Related]
5. Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.
Korfhage J; Lombard DB
Mol Cancer Res; 2019 Jul; 17(7):1417-1428. PubMed ID: 31023785
[TBL] [Abstract][Full Text] [Related]
6. Single-cell sequencing reveals activation of core transcription factors in PRC2-deficient malignant peripheral nerve sheath tumor.
Zhang X; Lou HE; Gopalan V; Liu Z; Jafarah HM; Lei H; Jones P; Sayers CM; Yohe ME; Chittiboina P; Widemann BC; Thiele CJ; Kelly MC; Hannenhalli S; Shern JF
Cell Rep; 2022 Sep; 40(12):111363. PubMed ID: 36130486
[TBL] [Abstract][Full Text] [Related]
7.
Oppel F; Ki DH; Zimmerman MW; Ross KN; Tao T; Shi H; He S; Aster JC; Look AT
Dis Model Mech; 2020 Aug; 13(8):. PubMed ID: 32651197
[TBL] [Abstract][Full Text] [Related]
8. Epigenomic Reordering Induced by Polycomb Loss Drives Oncogenesis but Leads to Therapeutic Vulnerabilities in Malignant Peripheral Nerve Sheath Tumors.
Wojcik JB; Marchione DM; Sidoli S; Djedid A; Lisby A; Majewski J; Garcia BA
Cancer Res; 2019 Jul; 79(13):3205-3219. PubMed ID: 30898839
[TBL] [Abstract][Full Text] [Related]
9. Clarifying the Distinction Between Malignant Peripheral Nerve Sheath Tumor and Dedifferentiated Liposarcoma: A Critical Reappraisal of the Diagnostic Utility of MDM2 and H3K27me3 Status.
Makise N; Sekimizu M; Kubo T; Wakai S; Hiraoka N; Komiyama M; Fukayama M; Kawai A; Ichikawa H; Yoshida A
Am J Surg Pathol; 2018 May; 42(5):656-664. PubMed ID: 29309298
[TBL] [Abstract][Full Text] [Related]
10. Malignant peripheral nerve sheath tumor: pathology and genetics.
Thway K; Fisher C
Ann Diagn Pathol; 2014 Apr; 18(2):109-16. PubMed ID: 24418643
[TBL] [Abstract][Full Text] [Related]
11. Loss of dimethylated H3K27 (H3K27me2) expression is not a specific marker of malignant peripheral nerve sheath tumor (MPNST): An immunohistochemical study of 137 cases, with emphasis on MPNST and melanocytic tumors.
Thangaiah JJ; Westling BE; Roden AC; Giannini C; Tetzlaff M; Cho WC; Folpe AL
Ann Diagn Pathol; 2022 Aug; 59():151967. PubMed ID: 35567887
[TBL] [Abstract][Full Text] [Related]
12. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR
Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027
[TBL] [Abstract][Full Text] [Related]
13. Beyond "Triton": Malignant Peripheral Nerve Sheath Tumors With Complete Heterologous Rhabdomyoblastic Differentiation Mimicking Spindle Cell Rhabdomyosarcoma.
Hornick JL; Nielsen GP
Am J Surg Pathol; 2019 Oct; 43(10):1323-1330. PubMed ID: 31107719
[TBL] [Abstract][Full Text] [Related]
14. BRAF mutation, TERT promoter mutation, and HER2 amplification in sporadic or neurofibromatosis-related neurofibromas and malignant peripheral nerve sheath tumors: do these molecules have a signature in malignant transformation?
Coskun S; Gamsizkan M; Yilmaz I; Yalcinkaya U; Sungur MA; Buyucek S; Onal B
APMIS; 2020 Sep; 128(9):515-522. PubMed ID: 32580246
[TBL] [Abstract][Full Text] [Related]
15. Malignant Peripheral Nerve Sheath Tumors Show Decreased Global DNA Methylation.
Nix JS; Haffner MC; Ahsan S; Hicks J; De Marzo AM; Blakeley J; Raabe EH; Rodriguez FJ
J Neuropathol Exp Neurol; 2018 Oct; 77(10):958-963. PubMed ID: 30169729
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Awakening of Viral Mimicry in Cancer.
Janin M; Esteller M
Cancer Discov; 2020 Sep; 10(9):1258-1260. PubMed ID: 32873618
[TBL] [Abstract][Full Text] [Related]
17. From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor.
Lemberg KM; Wang J; Pratilas CA
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32599735
[TBL] [Abstract][Full Text] [Related]
18. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
[TBL] [Abstract][Full Text] [Related]
19. Combined SHPments: An Effective Therapeutic Strategy for MPNST.
Aplin AE; Capparelli C
Cancer Res; 2021 Jan; 81(2):266-267. PubMed ID: 33452215
[TBL] [Abstract][Full Text] [Related]
20. Chromosomal translocations inactivating CDKN2A support a single path for malignant peripheral nerve sheath tumor initiation.
Magallón-Lorenz M; Fernández-Rodríguez J; Terribas E; Creus-Batchiller E; Romagosa C; Estival A; Perez Sidelnikova D; Salvador H; Villanueva A; Blanco I; Carrió M; Lázaro C; Serra E; Gel B
Hum Genet; 2021 Aug; 140(8):1241-1252. PubMed ID: 34059954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]